{"id":"intravenous-injection-of-177lu-octreotate","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hematologic toxicity (anemia, thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Renal toxicity"},{"rate":null,"effect":"Hepatic toxicity"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108490","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Octreotate is a peptide that mimics somatostatin and binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on neuroendocrine tumor cells. When labeled with the beta-emitting radioisotope lutetium-177, it delivers cytotoxic radiation directly to tumor cells while sparing normal tissues, resulting in cell death through DNA damage.","oneSentence":"177Lu-octreotate is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy to kill them.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:47.475Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors (NET) with somatostatin receptor expression"},{"name":"Gastroenteropancreatic neuroendocrine tumors (GEP-NET)"}]},"trialDetails":[{"nctId":"NCT04837885","phase":"PHASE2","title":"Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases","status":"RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-09-24","conditions":"Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour","enrollment":23},{"nctId":"NCT01842165","phase":"PHASE3","title":"177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2013-05","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":37},{"nctId":"NCT01860742","phase":"PHASE3","title":"Randomized Phase III of PRRT Versus Interferon","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2014-12","conditions":"Gastro-intestinal Neuroendocrine Tumors","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["177Lu-DOTATATE","Lutate"],"phase":"phase_3","status":"active","brandName":"Intravenous injection of 177Lu-octreotate","genericName":"Intravenous injection of 177Lu-octreotate","companyName":"Jules Bordet Institute","companyId":"jules-bordet-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"177Lu-octreotate is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy to kill them. Used for Neuroendocrine tumors (NET) with somatostatin receptor expression, Gastroenteropancreatic neuroendocrine tumors (GEP-NET).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}